Skip to main content

Table 2 New mutations detected in plasma ctDNA during treatment

From: Association of emergence of new mutations in circulating tumuor DNA during chemotherapy with clinical outcome in metastatic colorectal cancer

Patient ID Time point New mutation cHGVS pHGVS Function VAFs (%)
P06 Post-C2 KRAS c.38G > A p.G13D missense 0.36
P07 Post-C4 CDK13 c.604_605insT p.R202Lfs*68 frameshift 1.10
Post-C4 MTOR c.617G > A p.R206H missense 0.73
P08 Post-C4 BRCA2 c.6232G > A p.G2078R missense 0.90
Post-C4 MYC c.1211A > G p.K404R missense 0.32
Post-C4 FGFR2 c.269A > T p.E90V missense 0.56
Post-C4 EGFR c.2327G > A p.R776H missense 0.25
P10 Post-C4 PIK3R2 c.451C > T p.P151S missense 1.23
Post-C4 DNMT3A c.2077C > T p.R693C missense 0.57
Post-C4 NTRK1 c.1859G > A p.C620Y missense 0.60
Post-C4 MLL c.10480A > G p.N3494D missense 0.60
  1. cHGVS Coding DNA reference sequences (Human Genome Variation Society), pHGVS Protein level amino acid sequences (Human Genome Variation Society), Post-C2 After 2 cycles of chemotherapy, Post-C4 After 4 cycles of chemotherapy